Generic Zepbound®: Why it doesn’t exist yet—and when it might

Zepbound® has quickly gained attention as a powerful weight-loss medication. Its active ingredient, tirzepatide, can help people lose an average of 21% of their body weight over time. But, it’s also expensive, over $1,000 without insurance, so it’s no surprise that many people are searching for more affordable options. A common question is: Is there a generic version of Zepbound® or tirzepatide?

Right now, the answer is no. There isn’t currently a generic tirzepatide or Zepbound® available in the United States (or anywhere else for that matter). Zepbound® is protected by patents and regulatory exclusivity, which means generic versions aren’t yet able to be made.

The good news is that pricing and insurance coverage of tirzepatide and many GLP-1 medications like it are beginning to change. No one needs to pay full price for Zepbound®, and there are ways to save. 

But for the future, let’s take a look at why generic tirzepatide isn’t available and what typically needs to happen before it can be, and see how you can get the best price for Zepbound® right now.  

What is Zepbound^®—and why is cost so important?

Zepbound® is a weight loss medication that is injected once a week. People can lose an average of 20 to 21% of their body weight over the course of treatment.

Its active ingredient, tirzepatide, mimics two hormones (GLP-1 and GIP) to help lower appetite, slow digestion, and regulate blood sugar, making it easier to eat less and maintain a healthier way of eating.

What a medication is approved for is important when talking about cost, because often those approvals matter for insurance purposes. Coverage often depends on why the medication is prescribed.

When it comes to Zepbound® and medication used for weight loss, Insurance companies aren’t required to cover them. So even though Zepbound® is approved for it, many people still end up paying out of pocket. Zepound® is also approved for obstructive sleep apnea (OSA), so it might be approved if prescribed for that purpose. Its counterpart, Mounjaro®, which contains tirzepatide in the same dose, is sometimes approved for type 2 diabetes management. 

And that’s where the interest in a potential generic comes in.

Is there a generic Zepbound^®?

No, there isn’t a generic version of Zepbound® available right now.

Zepbound® is protected by patents and regulatory exclusivity. Because of that, it’s currently only available as a brand-name drug manufactured by Eli Lilly. 

Until those patents expire and other manufacturers are allowed to enter the market, Zepbound® will remain a brand-only medication. Based on current estimates, that could take several years, with potential generic competition not expected until at least the mid-2030s. 

Why Zepbound^® doesn’t have a generic yet

The short answer is patents.

The main patent protecting tirzepatide—the active ingredient in Zepbound^®—is expected to expire in January 2036. This patent covers the actual dual GIP/GLP-1 receptor agonist molecule. Until that protection runs out, no other company can make and sell a generic version in the United States.

But it’s not just the ingredient that’s protected. Eli Lilly also holds patents covering the autoinjector pen, the specific liquid formulation, and certain delivery methods. Some of those additional protections may extend until around 2041. That means even if tirzepatide becomes eligible for generic competition after 2036, companies may still need to design around device and formulation patents.

When will a generic Zepbound^® be available?

Most generic drugs reach the market 10 to 15 years after the original medication is approved. That delay exists because patents and regulatory exclusivities block competition during the early years. 

To understand what that timeline can look like, it helps to look at liraglutide, a medication that came before tirzepatide and followed a similar path from diabetes treatment to weight loss therapy and eventual generic availability. 

Liraglutide, like tirzepatide, belongs to the GLP-1 class of medications. Liraglutide is an earlier GLP-1 receptor agonist that must be injected daily. But, its development and approval timeline offers a useful roadmap for how these drugs typically evolve—and when generics may emerge.

Like tirzepatide, liraglutide has two medications with the active ingredient but approved for different purposes. Made by Novo Nordisk, the same company behind Ozempic and Wegovy, Victoza is approved for diabetes management, and Saxenda is approved for weight loss. 

Here’s the path it took to generic availability: 

• 2010 –  Victoza was approved for diabetes management.
• 2014 – Saxenda^® was approved for weight loss.
• Late 2023 – Victoza’s patent in the U.S. expired.
• 2024 – Teva Pharmaceuticals, in coordination with Novo Nordisk, announced the launch of an authorized generic of Victoza in the U.S, making it the first generic GLP-1 receptor agonist. Hikma Pharmaceuticals launched its generic version of Victoza on December 26, 2024.
• 2025 – In August, the FDA approved a generic version of Saxenda, making it the first generic GLP-1 approved for weight loss.

This timeline shows that it takes time for patents to expire, and generics can be approved for different indications at different rates. Generic liraglutide was first approved in Victoza doses for diabetes management, followed by Saxenda®-level doses for weight loss. But the path each medication takes varies. 

And timelines are estimates, not guarantees. Patent challenges, legal settlements, and manufacturing readiness all influence when generics actually reach the market. 

Generic companies often challenge patents before they expire, potentially speeding up availability. But ongoing litigation and the technical complexity of producing tirzepatide could push generic availability even further into the future.

For now, January 2036 remains the earliest widely cited date to watch, with actual generic availability dependent on patent outcomes and FDA approval.

When will the price of Zepbound® go down?

The price of Zepbound® has already started to decrease due to demand, recent pricing agreements, and expanded access programs.

In late 2025, new initiatives were introduced to help lower the cost of widely used weight loss medications like Zepbound®. These efforts are part of a broader push to align U.S. drug prices more closely with those in other developed countries, where people often pay significantly less.

For people currently facing Zepbound®’s list price of over $1,000 per month, these changes could make treatment more accessible.

Here’s a look at how things are changing :

• Lower cash prices (available now): People paying out of pocket can get Zepbound® through Lilly Direct for $299 to $449 per month.
• Medicare coverage (starting July 2026): Starting in 2026, Medicare is beginning to expand access to medications like Zepbound, with some eligible people able to pay as little as about $50 per month—but that price isn’t automatic. It applies to people who meet certain health criteria, are enrolled in participating Medicare drug plans, and go through standard steps like prior authorization. 
• Medicaid access (timeline varies): State Medicaid programs are also expected to expand access to lower-cost options, though rollout will differ depending on the state.

Read more: Does insurance cover Zepbound®? Check your coverage in 2026

Generic Zepbound® price: What could a future generic tirzepatide cost? 

Predicting the price of a future generic Zepbound® isn’t straightforward. In many cases, generic medications cost 80% to 90% less than brand-name versions—but that pattern doesn’t always hold, especially for newer injectable drugs like GLP-1 medications.

To get a sense of what might happen, it helps to look at current pricing and trends for similar drugs. The list price for Zepbound® is roughly $1,000 per month, which sets the baseline for potential savings if generic versions eventually become available.

Generic liraglutide as a reference point: When generic liraglutide entered the market, prices varied a lot. Larger 5-pen packages used for weight-loss dosing (comparable to Saxenda®) have ranged from about $370 to $1,240.

Here’s how that compares to the brand version:

Medication	Generic price (approx.)	Brand price
Saxenda® (liraglutide)	$370–$1,240 (5 pens)	$1,349/month

This shows that while generics can lower costs, the drop isn’t always dramatic—and prices can vary widely depending on pharmacy pricing, supply, and insurance coverage.

A future generic version of Zepbound® would likely cost less than the brand, but based on similar drugs, it may not be an 80 to 90% discount. And pricing could remain variable for some time after launch.

How do generic drugs actually work?

Generic drugs are true copies held to strict FDA standards designed to make sure they work the same way as the brand-name medication.

For a future generic version of Zepbound® to be approved, it would need to match the original drug in several key ways:

• the same active ingredient (tirzepatide)
• the same strength
• the same dosage form (in this case, an injection)
• the same route of administration (subcutaneous injection)

In other words, the generic has to replicate the parts of the drug that determine how it works in the body and how safely it can be used.

A central requirement in this process is something called bioequivalence. This means manufacturers must show that the generic enters the bloodstream at roughly the same speed and in the same amount as the brand-name drug. When that standard is met, the body processes both versions in essentially the same way, which is why most people don’t notice a difference when switching.

More questions about generic Zepbound^®

What’s the earliest Zepbound^® could come out as a generic?

Based on current patents, a generic Zepbound^® likely won’t be available until around 2036. Patent protections typically last 10 to 15 years after approval, though legal challenges could potentially change this timeline. Multiple patents currently protect tirzepatide’s formulation and manufacturing process.

Will insurance cover generic Zepbound^® when it’s available?

It’s too early to say with certainty, but the current landscape suggests coverage won’t be straightforward. Generics are typically placed on more favorable insurance tiers than brand-name drugs, which could help, but weight loss remains one of the most challenging categories for insurance coverage, regardless of whether a drug is brand-name or generic. A generic version could shift this dynamic over time, especially if lower prices make insurers more willing to expand access. 

Are generics always cheaper than brand-name drugs?

Generic medicines usually cost less because they’re allowed to enter the market only after brand-name drugs lose patent protection. By that point, the original company had already spent heavily on research and clinical trials. 

Generic manufacturers don’t repeat those full studies—they only have to prove to the FDA that their version works the same way in the body. With lower development costs and more companies competing in the market, prices often drop significantly, typically 80% to 85% lower than the brand-name version. 

What countries have generic tirzepatide, if any?

As of early 2026, no country offers an approved generic version of tirzepatide for weight loss or diabetes. Patent protections for tirzepatide extend across major global markets, which prevents true generics from being approved or widely distributed.

Semaglutide has started to move into the generic phase in some regions. India approved several generic versions in 2026 following patent changes, marking one of the first major markets to do so. Canada has now followed, becoming the first major developed country to approve a generic semaglutide injection. Availability is still expected to be limited at first as manufacturers ramp up production.

The bottom line: There is no generic Zepbound® or tirzepatide in the U.S.

Generic Zepbound^® remains unavailable, with patents protecting Zepbound^®  (and tirzepatide) until at least 2036. But the future of Zepbound^® pricing is already shifting due to manufacturer discount programs and policy negotiations that could lower costs significantly before any generic arrives.

If you’re exploring GLP-1 options, see if you qualify for Noom Med. You’ll be connected with a clinician who can help find the right medication for you and prescribe it if needed. You’ll also get medical guidance plus behavioral support to make the habit changes that make weight loss last long term. Check if you qualify and find out what your options look like.